Rhône-Poulenc Rorer continued its strategy of building core competency in gene and cell therapy, completing the acquisition of Applied Immune Sciences Inc. started in 1993.

Under the definitive merger agreement, RPR will pay AISX (Santa Clara, Calif.) $84.4 million in cash, or $11.75 a share for the 7.2 million shares not already held by the pharma company.